AstraZeneca initiates AZD9574 study in advanced solid malignancies
AstraZeneca is conducting a study to evaluate AZD9574's safety, tolerability, PK, PD, and preliminary efficacy in advanced solid malignancies.
Asset / Drug
Drug and asset intelligence for AZD9574 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.